Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-Guggulsterone SCHEMBL13327483 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL12153588 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL13304392 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL14193742 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL1650063 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL258031 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL177528 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL177786 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL12858540 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| Guggulsterone SCHEMBL141657 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399594-A1 | MORPHOGENIC COMPOUND-RELEASING MICROSPHERES AND USE IN BIOINK | UVIC INDUSTRY PARTNERSHIPS INC. (CA) | 2020-12-24 | — | — | US | disclosed |
| EP-2337847-B1 | VACCINE ADJUVANTS | CADILA PHARMACEUTICALS LTD (IN) | 2015-12-02 | — | — | EP | disclosed |
| US-8647643-B2 | Farnesoid-X-receptor antagonist as a vaccine adjuvant | CADILA PHARMACEUTICALS, LTD (IN) | 2014-02-11 | — | — | US | disclosed |
| US-8647643-B2 | Farnesoid-X-receptor antagonist as a vaccine adjuvant | CADILA PHARMACEUTICALS, LTD (IN) | 2014-02-11 | — | — | US | disclosed |
| EP-2594577-A1 | Process for preparing guggulsterones and guggulsterol | Seoul National University Industry Foundation (KR) | 2013-05-22 | — | — | EP | disclosed |
| EP-1620455-B1 | PROCESS FOR PREPARING GUGGULSTERONES AND GUGGULSTEROL | SEOUL NAT UNIV IND FOUNDATION (KR) | 2011-11-30 | — | — | EP | disclosed |
| US-20110182939-A1 | Vaccine Adjuvants | CADILA PHARMACEUTICALS LTD. (IN) | 2011-07-28 | — | — | US | disclosed |
| US-20110182939-A1 | Vaccine Adjuvants | CADILA PHARMACEUTICALS LTD. (IN) | 2011-07-28 | — | — | US | disclosed |
| EP-2284176-A1 | Process for preparing guggulsterones and guggulsterol | Seoul National University Industry Foundation (KR) | 2011-02-16 | — | — | EP | disclosed |
| EP-2251346-A2 | Process for preparing guggulsterones and guggulsterol | Seoul National University Industry Foundation (KR) | 2010-11-17 | — | — | EP | disclosed |
| WO-2010122407-A2 | HYPOLIPAEMIC PHARMACEUTICAL COMPOSITIONS | CADILA PHARMACUETICALS LTD. (IN) | 2010-10-28 | — | — | WO | disclosed |
| US-20100172870-A1 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20100172870-A1 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-07-08 | — | — | US | disclosed |
| WO-2010035119-A2 | VACCINE ADJUVANTS | CADILA PHARMACEUTICALS LTD. (IN) | 2010-04-01 | — | — | WO | disclosed |
| US-20080139520-A1 | Altering cholesterol and fat uptake by novel allosteric inhibitors of pancreatic phospholipase A2 | JAIN MAHENDRA K | 2008-06-12 | — | — | US | disclosed |
| WO-2008017692-A2 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2008-02-14 | — | — | WO | disclosed |
| US-20070055072-A1 | Process for preparing guggulsterones and guggulsterol | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2007-03-08 | — | — | US | disclosed |
| US-20070055072-A1 | Process for preparing guggulsterones and guggulsterol | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182939-A1 | Vaccine Adjuvants | FXR2, FXR1, NR1H4 | SMN1; SMN2 4846/4885HSD17B10 974/4885ALDH1A1 4615/4885 |
| US-20080139520-A1 | Altering cholesterol and fat uptake by novel allosteric inhibitors of pancreatic phospholipase A2 | PNLIP, PLA2G4B, PLA2G4A | SMN1; SMN2 3816/4885HSD17B10 504/4885ALDH1A1 4160/4885 |
| US-20100172870-A1 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | FXR1, FXR2, NR1H4 | SMN1; SMN2 4801/4885HSD17B10 457/4885ALDH1A1 4283/4885 |
| US-20070055072-A1 | Process for preparing guggulsterones and guggulsterol | CYP17A1, CYP46A1, HSD17B7 | SMN1; SMN2 4445/4885HSD17B10 48/4885ALDH1A1 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.